GU Oncology Now
GU Oncology Now delivers the latest news in therapeutics, clinical trials, conference coverage, and more, highlighting important advancements in genitourinary oncology treatments and technologies with the goal of better informing oncology decisions and improving patient outcomes.
EVOLUTION: Lu-PSMA With Ipi/Nivo in mCRPC
TheraP: Clonal Hematopoiesis in mCRPC Patients Receiving Lu-PSMA or Cabazitaxel
ProstACT GLOBAL: TLX591 and Best SOC for Patients With PSMA-Expressing mCRPC
VIOLET: Terbium-161 Radioligand Treatment in Patients With mCRPC
KEYNOTE-564 Follow-Up Leading to the STRIKE Trial
ARC-20: Casdatifan Plus Cabozantinib Expansion Cohort
Progress and Barriers With Real-World Combination Therapy in mHSPC
First-Line Zanza Combined With Checkpoint Inhibitors for the Treatment of Patients With ccRCC
Cabazitaxel vs Lutetium-177: Efficacy for Metastatic Castration-Resistant Prostate Cancer
KEYNOTE-564: 5-Year Follow-Up Results
Lutetium Leads the Way: Capitalizing on PSMAfore and PEACE-3
Striking the Right Balance: Sequencing and Tolerability in Modern mCRPC Trials
Precision in Progress: The Role of MDT and Genetic Testing in Advanced PCa
Darolutamide in the Real World: From ARANOTE to Actionable Risk Assessment
Triplet Therapy: Who, When, and Why
When PET Misleads: Clinical Nuance in Low-Volume mCSPC
Defining mCRPC Versus mCSPC: Hormonal Sensitivity, Resistance, and the Role of Testosterone
NIAGARA: ctDNA in Patients With MIBC Who Received Perioperative Durvalumab
ENLIGHTED: Padeliporfin VTP Offers High CR Rate in Low-Grade UTUC
CREST: EFS Subgroup Analyses Based on Disease Stage
BULLSEYE: Lu-PSMA in Oligometastatic HSPC
HPK1 Inhibition in Clear Cell RCC: NDI-101150
Circulating, TME Determinants of Response for Patients in Checkmate 9ER
PDIGREE: New Insights on Tolerability, Treatment Response of 1L Ipi/Nivo for mccRCC
ENZA-p: Predictive, Prognostic Value of Baseline PSMA Total Tumor Volume, SUV Mean
ASCO Annual Meeting Preview: Prostate Cancer
ASCO Annual Meeting Preview: Kidney Cancer
ASCO Annual Meeting Preview: Bladder Cancer
HRR Mutations and mCRPC: When and How to Integrate PARP Inhibitors
Darolutamide, ARANOTE, and Navigating Payment